Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb;11(2):213–223. doi: 10.21037/tlcr-22-88

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2022 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

The composition ratio of G13X in KRAS/TP53 co-mutation is significantly higher than Q61X in blood. (A) The frequency of KRAS comutation subtype in blood samples of 69 non-small cell lung cancer (NSCLC) patients, including KRAS/TP53 (KP), KRAS/STK11 (KL), KRAS/CDKN2A (KC), and KRAS mutation (without TP53, STK11, and CDKN2A); (B) the expression level of tumor mutation burden (TMB) in KRAS subtype mutations, including KL, KP, KC, and KRAS (n=69); (C) the frequency of KRAS subtype mutation in blood samples (n=69); (D) the frequency of KRAS subtype mutation in blood samples with KRAS/TP53 mutation (n=32). *, P<0.05; ****, P<0.0001.